Protein C polymorphisms
The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition.
1. A method for determining a prognosis for a human subject having, or at risk of developing, an inflammatory condition, the method comprising determining a genotype of said human subject at a polymorphic site in the subject's protein C gene at position 2418 of SEQ ID NO:1, wherein said genotype is indicative of the subject's ability to recover from the inflammatory condition which is SIRS, sepsis or septic shock, wherein the relationship between the nucleotide at said position 2418, the inflammatory condition and the prognosis is as follows:
(a) for SIRS, sepsis or septic shock:
(i) sense strand 2418AA homozygosity, or antisense strand 2418TT homozygosity, is prognostic of a decreased ability to recover; and
(ii) sense strand 2418GG homozygosity, or antisense strand 2418CC homozygosity, is prognostic of an increased ability to recover; and
(b) for septic SIRS:
sense strand 2418AG heterozygosity or antisense strand 2418TC heterozygosity is prognostic of an increased ability to recover compared to that of 2418AA homozygosity and a decreased ability to recover compared to that of 2418GG homozygosity.
2. The method of claim 1 , further comprising determining the sequence of protein C of the subject.
3. The method of claim 1 , wherein the genotype is determined using a nucleic acid sample from the subject.
4. The method of claim 3 , which further comprises obtaining the nucleic acid sample from the subject.
5. The method of claim 1 , wherein said genotype is determined using one or more of the following techniques:
(a) restriction fragment length analysis;
(b) sequencing;
(c) hybridization;
(d) oligonucleotide ligation assay;
(e) ligation rolling circle amplification;
(f) 5′ nuclease assay;
(g) polymerase proofreading;
(h) allele specific PCR; and
(i) reading sequence data.
6. The method of claim 1 , wherein the subject is critically ill, and has a genotype prognostic of decreased ability to recover from the inflammatory condition and from severe cardiovascular or respiratory dysfunction present in said inflammatory condition.
7. The method of claim 1 , wherein the subject is critically ill, and has a genotype prognostic of increased ability to recover from the inflammatory condition and from mild cardiovascular or respiratory dysfunction present in said inflammatory condition.
8. The method of claim 1 , wherein the inflammatory condition is SIRS.